ArticleInflammopharmacology2026
Multi-target modulation of inflammatory pathways by Colchicum luteum in rheumatoid arthritis through experimental and in silico evidence.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic, complex systemic inflammatory disease characterized by synovial inflammation, hyperplasia, angiogenesis, cartilage and bone destruction. Research into naturally derived herbal medicine has gained significant interest. We endeavored in our study to evaluate phytochemicals, phenolic and flavonoid content and multi-modal anti-arthritic and immunomodulatory effect of ethanolic extract of Colchicum luteum (EECL). GC-MS analysis reported 40 phytocompounds, Pentanoic acid (6.77%), cis-vaccenic acid (7.03%), Di-isopropylethylamine (6.46%) and morpholine (19.44%) with highest peak. In vitro egg albumin assay surpassed protein denaturation in concentration dependant manner. In CFA induced arthritis model, 100, 200 and 400 mg/kg EECL demonstrated dose-dependent significant effects (p < 0.05) in paw diameter, arthritic score, body weight, and organs weight. Histopathological analysis showed marked reduction in inflammation, pannus development and blood cell infiltration. Hematological, biochemical, and oxidative marker were normalized in treatment groups as compared to arthritic control (p < 0.05). The extract persuasively down-regulated the COX-2, PGE2, IL-1β, IL-6, NF-κβ, and TNF-α, and up-regulated the mRNA expression of I-κB, IL-4, and IL-10. Moreover, Phytocompounds were screened following the Lipinski rule and drug bioavailability properties. PPI network construction evaluated PTGS2, PPARG PTGS1, ALOX5, ESR1, PTGES, NR3C1, PTPRC, MAPK1 and PLA2G4A as common targets of RA. GO and Kegg pathway analysis revealed C. luteum involved in eicosanoid biosynthesis, prostaglandin synthesis, inflammatory responses and arachidonic acid metabolism. Molecular docking analysis demonstrated strong binding affinity of 2-ethylacridine with the COX-2 active site, indicating its potential inhibitory activity against inflammatory mediators. Furthermore, MD simulation confirmed the stability of the ligand COX-2 complex, supporting the reliability of docking results and reinforcing the anti-inflammatory potential of C. luteum. This study provides novel approach that rationalizes C. luteum corms traditional use in arthritis treatment and supports its phytotherapeutic application.
Indexed as
Identifiers
41888385What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.